Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Estrone sulfate
Drug ID BADD_D00835
Description Estrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis.
Indications and Usage Estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB04574
KEGG ID D00312
MeSH ID C017296
PubChem ID 3001028
TTD Drug ID Not Available
NDC Product Code Not Available
UNII QTL48N278K
Synonyms estrone sulfate | oestrone sulphate | estrone-3-sulfate | estrone sulfate, 16-(14)C-labeled | Evex | estrone sulfate, potassium salt | potassium estrone sulfate | estrone sulfate, sodium salt | sodium estrone sulfate | estrone sulfate, 14C-labeled | estrone sulfate, ammonium salt
Chemical Information
Molecular Formula C18H22O5S
CAS Registry Number 481-97-0
SMILES CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin disorder23.03.03.007---
Somnolence17.02.04.006; 19.02.05.003--
Tenderness08.01.08.005---
Tension19.06.02.005---
Thrombophlebitis24.01.02.001---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urticaria10.01.06.001; 23.04.02.001--
Uterine haemorrhage21.07.01.005; 24.07.03.004--
Uterine leiomyoma16.04.02.001; 21.07.02.004---
Vaginal discharge21.08.02.002--
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection11.01.10.002; 21.14.02.002--
Venous thrombosis24.01.01.008---
Vertigo04.04.01.003; 17.02.12.002--
Vomiting07.01.07.003--
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Weight increased13.15.01.006--
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Musculoskeletal discomfort15.03.04.001---
Endometrial thickening21.07.01.013---
Angiopathy24.03.02.007---
Breast disorder21.05.04.004---
Cardiac disorder02.11.01.003---
Infestation11.09.01.001; 23.11.01.002---
Malnutrition14.03.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
Porphyrin metabolism disorder03.08.01.006; 09.01.10.004; 14.14.01.006---
Polyp08.01.06.010; 16.02.02.005---
Hepatobiliary disease09.01.08.003---
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages